DEF 14A: Renalytix Seeks Shareholder Approval for Key Resolutions at Upcoming General Meeting

Renalytix is convening a General Meeting on October 31, 2024, to seek shareholder approval for resolutions including share allotment, director appointment, and disapplication of pre-emption rights to support the company's fundraising and strategic initiatives.

Summary

• Renalytix plc is holding a General Meeting on October 31, 2024, to vote on three resolutions.
• Resolution 1 seeks authorization for the Board to allot new ordinary shares and issue senior convertible bonds up to a maximum aggregate nominal value of $7,880,744.
• This includes allotments for Non-EIS/VCT Placing Shares (171,915.373), Conversion Shares (91,376.358), Subscription Shares (95,969.085), and additional shares/rights up to 291,932.91 (approximately 35% of the Enlarged Issued Share Capital).
• Resolution 2 proposes the appointment of Julian Baines as a director of the Company, effective from the close of the General Meeting.
• Resolution 3 requests the disapplication of pre-emption rights for the allotment of equity securities for cash, as granted by Resolution 1, up to specified nominal amounts for Non-EIS/VCT Placing Shares, Conversion Shares, Subscription Shares, New Convertible Bonds, and additional equity securities.
• The Board of Directors unanimously recommends voting in favor of all resolutions.
• The company had previously placed 131,161,556 new ordinary shares at 9 pence per share, raising approximately 11.8 million.
• The net proceeds from the fundraise are expected to be used predominantly for sales and marketing and general corporate and administrative expenses.
• The meeting will be held at 6 Stratton Street, London W1J 8LD at 12 noon (GMT).

Sentiment

Score: 7

Explanation: The document is generally positive, focusing on securing shareholder support for strategic initiatives and fundraising. The unanimous recommendation from the Board adds to the positive sentiment, although the need for additional funding and the serious loss of capital are potential concerns.

Positives

• The proposed resolutions aim to strengthen the company's financial position and support its growth plans.
• The appointment of Julian Baines brings significant experience in the life science industry to the Board.
• The fundraise will provide capital for sales and marketing and general corporate and administrative expenses.
• The Board of Directors unanimously recommends voting in favor of all resolutions, indicating strong internal support.

Negatives

• The company had to allot and issue 24,007,773 Ordinary Shares (the EIS/VCT Placing Shares) without obtaining shareholder approval.
• The company is seeking authority to allot and issue 68,766,149 Ordinary Shares, all of which will be non-EIS/VCT qualifying (the Non-EIS/VCT Placing Shares), allot and issue 36,550,543 Ordinary Shares in return for the conversion of a certain proportion of the debt and accounts payable balance owed by the Company (the Conversion Shares) and allot and issue 38,387,634 Ordinary Shares, which will be used to satisfy the subscriptions by certain subscribers (the Subscription Shares) (the Placing Shares) and to issue $7,880,744 new unsecured convertible bonds as part of the restructuring of the 8.7 million amortizing senior convertible bonds held by a fund advised by Heights Capital Ireland LLC (the New Convertible Bonds), conditional upon the passing of Resolutions 1 and 3 set out in the Notice of General Meeting.

Risks

• Failure to obtain shareholder approval for the resolutions could significantly constrain the company's ability to fund its business development.
• The company is required, pursuant to section 656 of the Act, to convene a general meeting for the purpose of allowing shareholders to consider whether any, and, if so, what, steps should be taken to deal with the situation as the value of the Company's net assets is less than half of its called-up share capital (constituting a serious loss of capital under the Act).

Future Outlook

The company intends to use the net proceeds of the Fundraise predominantly for sales and marketing and general corporate and administrative expenses.

Management Comments

• The Board of Directors believes that each Resolution is in the best interest of shareholders and most likely to promote the success of the Company for the benefit of its shareholders as a whole.
• Accordingly, the Board of Directors unanimously recommends that you vote in favor of each of the Resolutions.

Industry Context

The life science industry is characterized by the need for continuous funding to support research, development, and commercialization efforts. Renalytix's fundraise and proposed resolutions align with this industry trend.

Comparison to Industry Standards

• Capital raises are common in the diagnostics and biotech industries, with companies like Verici Dx plc (where Julian Baines is also Non-Executive Chairman) also requiring funding to advance their technologies.
• Convertible bonds are a typical financing instrument used by growth companies to raise capital without immediate equity dilution, similar to offerings by companies like Oxford Nanopore Technologies.

Management Changes

Related Party Transactions

• James McCullough, Christopher Mills, Catherine Coste and Fergus Fleming (members of our Board) and Joel Jung (our Interim CFO), have subscribed for certain Placing Shares.
• Icahn School of Medicine at Mount Sinai has also subscribed for certain Subscription Shares.

Stakeholder Impact

• Shareholders: Approval of the resolutions is intended to benefit shareholders by strengthening the company's financial position and supporting growth.
• Employees: The fundraise is expected to support sales and marketing efforts, potentially leading to increased business activity and job security.
• Customers: Improved financial stability and growth could lead to enhanced product offerings and customer service.

Next Steps

• Shareholders to vote on the resolutions by the specified deadlines.
• The company to hold the General Meeting on October 31, 2024.
• The company to announce the results of the voting at the Meeting and via SEC filing and RNS announcement.

Key Dates

Keywords

Renalytix, General Meeting, Shareholder Vote, Share Allotment, Director Appointment, Pre-emption Rights, Convertible Bonds, Fundraise, Ordinary Shares, Resolutions